ZyVersa Therapeutics Past Earnings Performance
Past criteria checks 0/6
ZyVersa Therapeutics's earnings have been declining at an average annual rate of -89.1%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-89.1%
Earnings growth rate
-89.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -887.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ZyVersa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -106 | 11 | 3 |
30 Sep 23 | 0 | -88 | 11 | 5 |
30 Jun 23 | 0 | -98 | 10 | 6 |
31 Mar 23 | 0 | -14 | 7 | 6 |
31 Dec 22 | 0 | -14 | 8 | 6 |
30 Sep 22 | 0 | -21 | 6 | 5 |
30 Jun 22 | 0 | -10 | 6 | 3 |
31 Mar 22 | 0 | -10 | 7 | 3 |
31 Dec 21 | 0 | -8 | 6 | 2 |
Quality Earnings: ZVSA is currently unprofitable.
Growing Profit Margin: ZVSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ZVSA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ZVSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZVSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ZVSA has a negative Return on Equity (-887.6%), as it is currently unprofitable.